Soluble Leishmania Antigens Plus Pristane Adjuvant Induce Partial Cross-protection Against Leishmaniasis in BALB/c mice

Byrum Wabwoba^1, , Damaris Matoke-Muhia², Johnston Ingonga², Japheth Lusweti² and Michael Gicheru³

¹Kenya Coast National Polytechnic, Department of Applied Sciences, Mombasa, Kenya

²Center for Biotechnology Research and Development, Kenya Medical Research Institute, Nairobi, Kenya

³Department of Zoological Sciences, Kenyatta University, Nairobi, Kenya

Cite this paper:
Byrum Wabwoba, Damaris Matoke-Muhia, Johnston Ingonga, Japheth Lusweti and Michael Gicheru. Soluble Leishmania Antigens Plus Pristane Adjuvant Induce Partial Cross-protection Against Leishmaniasis in BALB/c mice. American Journal of Infectious Diseases and Microbiology. 2025; 13(1):26-31. doi: 10.12691/ajidm-13-1-4

Abstract

Leishmaniasis is a vector-borne parasitic disease of global concern. The disease is currently controlled by vector management and treatment of infected individuals as there is no approved vaccine. This study evaluated the safety, immunopotency and cross-immunity in BALB/c mice vaccinated with soluble Leishmania major or L. donovani antigens co-administered with 2,6,10,14-tetramethylpentadecane (pristane) and challenged with either L major or L.donovani virulent parasites. Safety was assessed by establishing dose-dependent blood-cell and platelet counts at 28 days post-injection, immunopotency was determined by measurement of interferon-gamma (IFN-ɣ) and interleukin 10 (IL-10) production, and disease progression by measurement either footpad lesion and parasite load in case of L.major challenge or spleen parasite loads for L.donovani challenge at 45 days post-infection. There was no significant effect by pristane on blood cell and platelet counts, indicating that at 20ug/mL, pristane was safe to use as an adjuvant in mice. Mice vaccinated with soluble L. donovani antigens plus pristane and challenged with L. major had smaller infected footpad lesions and lower parasite loads compared to BCG-vaccinated and unvaccinated mice. Similarly, mice vaccinated with soluble L. major antigens plus pristane and challenged with L. donovani had lower splenic parasite loads than unvaccinated mice. These corresponded with increased production of IFN-ɣ and suppressed production of IL-10 in each of the vaccinated groups, suggesting an up-regulated protective T helper 1 (Th1) response. The results indicated that vaccination of BALB/c mice with pristane adjuvant co-administered with soluble Leishmania antigens promotes Th1 response that confers partial cross-immunity against infection with heterologous Leishmania parasites. Further investigations on the safety of pristane in the longer term as well as other factors other than Th1 cytokines production up-regulation that may influence cross-protection in Leishmania infections need to be investigated

Keywords:
pristane adjuvant leishmaniasis cross-protection BALB/c mice

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Barbosa, G. de C.Y.M., Shanmugam, S., Sarafini, M.R. and Araujo, A.D.D. Pharmaceutical agents for treatment of leishmaniasis: a patent landscape. Expert Opinion on Therapeutic Patents. 30. 633-41. Aug. 2020.
[2]	Wamai, R.G., Kahn, J., McGloin, J. and Ziaggi, G. Visceral leishmaniasis: a global overview. Journal of Global Health Science. 2(1): 23-42. Jun. 2020.
[3]	Garrido-Jareno, M., Sahuquillo-Torralba, A. and Chouman-Arcas, R. Cutaneous leishmaniasis: experiences of a Mediterranean hospital. Parasites and Vectors. 13:24. Jan. 2020.
[4]	WHO. Leishmaniasis, status of endemicity of cutaneous leishmaniasis: 2019. (2020-06-15) [2020-09-08]. Available: Https://Apps Who Int/ Neglected_diseases/ Ntddata/ Leishmaniasis/Leishmaniasis HtmL. Sept. 2019
[5]	Ikeogu NM, Akaluka GN, Chidalu AE, Enitan SS, Chukwunonso O, Aida FB, and Jude EU. Leishmania Immunity: Advancing Immunotherapy and Vaccine Development. Microorganisms. v.1201(8): 1-21. Aug. 2020.
[6]	Lopes MF, Costa-da-Silva AC, DosReis GA. Innate immunity to Leishmania infection: Within phagocytes. Mediators of Inflammation. 754965. July. 2014.
[7]	Liew FY, Li Y, Millott S. Tumour necrosis factor (TNF-alpha) in leishmaniasis. II. TNF-alpha-induced macrophage leishmanicidal activity is mediated by nitric oxide from L-arginine. Immunology. 71: 556–559. Dec. 1990.
[8]	Mutiso J, Macharia J, Kiio MM, Gicheru MM. Development of Leishmania vaccines: predicting the future from past and present experience. Journal of Biomedical Research. 27(2):85-102. March. 2013.
[9]	Dinc, R. Leishmaniasis Vaccines: The current situation and its promising aspect for the future. Korean Journal of Parasitology. 60(6): 379-391. Dec. 2022.
[10]	Tonui, W.K. and Titus, R.G. Cross-protection against Leishmania donovani but not L. braziliensis caused by vaccination with L. major soluble promastigote exogenous antigens in BALB/c mice. The American Journal of Tropical Medicine and Hygiene. 76(3). March. 2007.
[11]	Porozzi, R., Antonio, T., Amaral, V. and Grimaldi, G. Cross-immunity experiments between different species or strains of Leishmania in Rhesus macaques (Macaca mulatta). The American Journal of Tropical Medicine and Hygiene. 71(3). Oct. 2004.
[12]	Gicheru MM, Olobo JO and Anjili CO. Heterologous protection by L. donovani for L. major infection in the vervet monkey model of the disease. Experimental Parasitology. 85:109-116. Feb. 1997.
[13]	Madera R, Burakova Y, Shi J. emulsion adjuvants for use in veterinary vaccines. Met. Mol. Biol. 2022. 2412: 247-253.
[14]	Diehl EJ, Lutz DL, Rodenberg JH, and Kumar M. Emulsion vaccine composition comprising antigen and adjuvant in aqueous phase. World Intellectual Property Organization. 157659. A1. Dec. 2008.
[15]	Avigan J, and Blumer M. On the origin of pristane in marine organisms. Journal of Lipid Research. 9: 350–352. May. 1968.
[16]	Ouyang Q, Ziyang H, Zhenhua W, Xiaoqing C, Jingqin Ni, Ling Lin. Effects of pristane alone or combined with chloroquine on macrophage activation, oxidative stress, and Th1/Th2 skewness. Journal of Immunological Research. V.2014: July. 2014.
[17]	Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry. 72: 248. May. 1976.
[18]	Stone HD, Brugh M, Beard CW. Influence of formulation on the efficacy of experimental oil emulsion in Newcastle disease vaccines. Avian Diseases. 27(3): 688-697. July. 1983.
[19]	Lima HC, Bleyenberg J, Titus RG. A simple method for quantifying Leishmania in tissues of infected animals. Parasitology Today. 13(2): 80-82. Feb. 1997.
[20]	Bradley DJ and Kirkley J. Regulation of Leishmania population within the host. The variable course of Leishmania donovani infections in mice. Clinical Experimental Immunology. 30: 119-129. Oct. 1968.
[21]	Mbati PA, Anjili CO, Kagai JM, Githure JI. Pristane (2,6,10,14-tetramethyl-pentadecane) inhibits disease progression in Leishmania-infected BALB/c mice. African Journal of Health Sciences. 1(4): 157–159. Nov. 1994.
[22]	Camargo ME and Rebonato C. Cross reactivity in immunofluorescent test for Trypanosoma and Leishmania antibodies. American Journal for Tropical Medicine and Hygiene. July. 1969.